SCHEMBL6466347

SCHEMBL6466347

CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)c1nc2ccccc2o1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CTSK P43235 12/20 0.58
CTSL P07711 6/20 0.55
CTSB P07858 5/20 0.55
CTSS P25774 3/20 0.55
CAPN1 P07384 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6667415 0.86 PSMB5 (0.49) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL7049064 0.84 CTSL (0.55) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL5496377 0.80 CTSK (0.57) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL5494162 0.80 CTSK (0.57) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL5493843 0.80 CAPN1 (0.54) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL950389 0.79 ELANE (0.51)
SCHEMBL14370039 0.79 ELANE (0.51)
SCHEMBL952481 0.79 ELANE (0.51)
SCHEMBL5492840 0.79 CTSK (0.56) CTSKCTSLCTSBCTSSCAPN1
SCHEMBL5492843 0.79 CTSK (0.56) CTSKCTSLCTSBCTSSCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US claimed
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ CTSK 32/4885CTSL 18/4885CTSB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.